Aims and Scope of Advances in Therapy
Advances in Therapy is a monthly peer-reviewed medical journal covering clinical medicine, especially research on pharmaceuticals. The Managing Editor is Clare Shepherd. The journal publishes original clinical research papers and review articles. The journal was established in 1984 and published by Health Communications. Since 2008 it has been published by Springer Science+Business Media. Less
Key Metrics
CiteScore 

5
Eigenfactor 

0.005 - 0.01
H-Index 

74
Impact Factor 

< 5
Scite Index 

0.88 5-Year SI

SJR 

Q1Pharmacology (medical)

SNIP 

1.37
Recommended pre-submission checks
Powered by 

Topics Covered on Advances in Therapy
Advances in Therapy Journal Specifications
Indexed in the following public directories
Web of Science
Scopus
SJR
| Overview | |
| Publisher | SPRINGER |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1984 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Advances in Therapy ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Advances in Therapy
Real-World Risk of Myelodysplastic Syndrome/Acute Myeloid Leukemia and Other Second Primary Malignancies in Patients with Epithelial Ovarian Cancer Treated with Niraparib Maintenance Therapy: Results from a Postauthorization Safety Study.
- 20 May 2026
- Advances in therapy
Moderate and Severe Exacerbations and Healthcare Resource Utilization in Chinese Patients with COPD on Triple Therapy: A Retrospective Database Study.
- 20 May 2026
- Advances in therapy
Safety and Effectiveness of Guanfacine Hydrochloride Extended-Release in Adult Patients with ADHD in Japan: A Post-Marketing Surveillance Study.
- 20 May 2026
- Advances in therapy
Post Hoc Analysis of Recombinant C1 Inhibitor Clinical Data Using Contemporary Endpoints for Hereditary Angioedema.
- 20 May 2026
- Advances in therapy
A Phase IV, Randomized, Double-Blind, Crossover Study to Compare the Clinical Safety and Efficacy of AbobotulinumtoxinA and OnabotulinumtoxinA in Adult Upper Limb Spasticity.
- 20 May 2026
- Advances in therapy
Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 Trial.
- 19 May 2026
- Advances in therapy
Real-World Risk of Myelodysplastic Syndrome/Acute Myeloid Leukemia and Other Second Primary Malignancies in Patients with Epithelial Ovarian Cancer Treated with Niraparib Maintenance Therapy: Results from a Postauthorization Safety Study.
- 20 May 2026
- Advances in therapy
Moderate and Severe Exacerbations and Healthcare Resource Utilization in Chinese Patients with COPD on Triple Therapy: A Retrospective Database Study.
- 20 May 2026
- Advances in therapy
Safety and Effectiveness of Guanfacine Hydrochloride Extended-Release in Adult Patients with ADHD in Japan: A Post-Marketing Surveillance Study.
- 20 May 2026
- Advances in therapy
Post Hoc Analysis of Recombinant C1 Inhibitor Clinical Data Using Contemporary Endpoints for Hereditary Angioedema.
- 20 May 2026
- Advances in therapy
A Phase IV, Randomized, Double-Blind, Crossover Study to Compare the Clinical Safety and Efficacy of AbobotulinumtoxinA and OnabotulinumtoxinA in Adult Upper Limb Spasticity.
- 20 May 2026
- Advances in therapy
Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 Trial.
- 19 May 2026
- Advances in therapy